| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/31/2008 | US20080182802 Spiroheterocyclic glycosides and mehtods of use |
| 07/31/2008 | US20080182801 Core 2 glcnac-t inhibitors |
| 07/31/2008 | US20080182800 Composition for preventing or treating degenerative brain diseases comprising a hydrolysate of ginsenosides |
| 07/31/2008 | US20080182799 Botulinum toxin screening assays |
| 07/31/2008 | US20080182798 Novel effectors of dipeptidyl peptidase IV |
| 07/31/2008 | US20080182794 Methods for treating breast cancer using nrif3 related molecules |
| 07/31/2008 | US20080182792 Diminishing presence of protein aggregates in an environment susceptible to formation of protein aggregate by introducing into environment a compound having two domains, a first domain that binds to protein aggregation having two monomers, and a second domain binding to diminishing protein |
| 07/31/2008 | US20080182788 Compositions and Methods for Increasing Bone Mineralization |
| 07/31/2008 | US20080182780 Insulin or a peroxisome proliferator-activated receptor (PPAR) agonist |
| 07/31/2008 | US20080182776 Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process foe the preparation thereof |
| 07/31/2008 | US20080182752 Utilization of Rare Sugars in Plant or Microorganism |
| 07/31/2008 | US20080182314 Neuronal serine threonine protein kinase |
| 07/31/2008 | US20080182302 Open reading frames which encode polypeptides sufficient to direct the biosynthesis synthesis of a safracin molecule having improved properties and that could be used in the hemi-synthesis of new ecteinascidins compounds; combinatorial chemistry; antitumor agents; broad-spectrum antibiotics; bactericides |
| 07/31/2008 | US20080182276 Method and Quantification Assay for Determining c-kit/SCF/pAKT Status |
| 07/31/2008 | US20080181972 alpha -lipoic acid, ascorbic acid, and alpha -tocopherol, optionally one or more other antioxidants, beneficial minerals, and/or nutritional or dietary materials; diabetic retinopathy or diabetic macular edema, cataract, glaucoma, ocular inflammation |
| 07/31/2008 | US20080181971 antibiotic; synergistic with one or more of 5-fluorouracil, bortezomib, camptothecin, carmustine, cisplatin, doxorubicin, etoposide, gemcitabine, methotrexate, and paclitaxel;anticarcinogenic ; human and veterinary medicine |
| 07/31/2008 | US20080181966 Modafinil pharmaceutical compositions |
| 07/31/2008 | US20080181963 Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide |
| 07/31/2008 | US20080181962 Formulation process method to produce spray dried products |
| 07/31/2008 | US20080181960 Solid dispersion of completely amorphous carotenoids; polyvinylpyrrolidone, hydroxypropylcellulose hydroxypropylmethylcellulose solubility-enhancing polymers;spray dried powder increased bulk density; substantially free of lipids and oils |
| 07/31/2008 | US20080181959 Cinacalcet hydrochloride trade name SENSIPAR treat hyperparathyroidism in patients with chronic kidney disease on hemodialysis; povidone, poloxamer, hydroxypropyl methylcellulose; sucrose, mannitol, lactose; cinacalcet and carrier melt form a fusion product; hot melt extrusion system |
| 07/31/2008 | US20080181957 Increased amorphous stability of poorly water soluble drugs by nanosizing |
| 07/31/2008 | US20080181955 Resveratrol amount sufficient to permit release of nitric oxide (NO) during sexual stimulation; polyphenol to inhibit formation of type 5 phosphodiesterase; dry powder derived from grapes that are pressed to remove water; dried and then ground into the dry powder |
| 07/31/2008 | US20080181953 Composition containing a tensioning polymer and hybrid particles, methods of use |
| 07/31/2008 | US20080181948 Solid pharmaceutical dosage formulations |
| 07/31/2008 | US20080181947 Controlled release dosage form of tacrolimus |
| 07/31/2008 | US20080181946 Controlled Release Delivery System For Metformin |
| 07/31/2008 | US20080181945 Method for the treatment of acne |
| 07/31/2008 | US20080181944 semipermeable walled container that houses a capsule comprising a drug formulation, a piston, and an osmotic composition; releases the drug through a passageway at controlled rate over a sustained release period of time; progestin and estrogen |
| 07/31/2008 | US20080181943 short-acting agent selected from: GABA-A receptors modulators, benzodiazepine, phenothiazine, melatonin derivative and melatonin agonist; long-acting agent selected from: GABA-A receptors modulators, benzodiazepine, 5HT2A receptor antagonist and calcium ion modulator; sleep disorders |
| 07/31/2008 | US20080181942 inter alia, treating and/or preventing symptoms; Spasticity |
| 07/31/2008 | US20080181941 Inert pharmaceutically acceptable substrates containing an analgesic with diameter of .1 mm-3 mm, effective blood levels for at least 24 hours; Opioids; solid dosage form; sustained release |
| 07/31/2008 | US20080181940 Method For Accelerating Expression of CPT-1 |
| 07/31/2008 | US20080181939 hydrolysis triggered, controlled release polymersome nano-system for delivering a cytotoxic, anticancer therapeutic active agent to cell; stable, synthetic, self-assembling, controlled release, polyethylene oxide-based vesicles; semi-permeable, thin-walled, amphiphilic, high molecular weight |
| 07/31/2008 | US20080181937 Vitamin C, Vitamin E, DHA and Curcumin; treating an individual who is at increased risk of developing Alzheimer's disease because of family history |
| 07/31/2008 | US20080181936 dialdehyde cellulose (DAC) carrier; chemically immobilized blood coagulation factor selected from chitosan and gelatin; bacteriolytic agent selected from the group consisting of a lysozyme enzyme, silver nitrate, and chlorhexidine; chemically immobilized tranexamic acid or epsilon -aminocaproic acid |
| 07/31/2008 | US20080181933 for reducing nicotine addiction; including a water insoluble base portion; a water soluble portion |
| 07/31/2008 | US20080181930 Punctal Plugs and Methods of Delivering Therapeutic Agents |
| 07/31/2008 | US20080181928 stent; coating comprising a dry film comprising at least one lipid bilayer and at least one pharmaceutically effective agent; Upon exposure to an aqueous fluid, liposomes are released |
| 07/31/2008 | US20080181927 Device for local and/or regional delivery employing liquid formulations of therapeutic agents |
| 07/31/2008 | US20080181918 Immunogens; vaccines; fusion proteins |
| 07/31/2008 | US20080181909 Chimeric immunomodulatory compounds and methods of using the same |
| 07/31/2008 | US20080181906 For inducing neutralizing antibodies against HIV; hairpin motif; HIV gp120; hydrogen bonding |
| 07/31/2008 | US20080181901 Protein modulator of the plasma membrane Na,K-ATPase |
| 07/31/2008 | US20080181896 Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers |
| 07/31/2008 | US20080181894 Tumor/cancer antigens; solid phase synthesis; drug screening |
| 07/31/2008 | US20080181889 antagonist of epithelial membrane protein-2, blocking the entry of Chlamydia into the host cell; biodrug for treating gramnegative bacteria intracellular prokaryotic pathogens; drug screening |
| 07/31/2008 | US20080181885 202P5A5 gene or fragment or its encoded protein, or variants , or a fragment, used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 202P5A5 be used in active or passive immunization; gene therapy, immunotherapy; anticarcinogenic agent biodrug for pancreatic cancer |
| 07/31/2008 | US20080181884 administering a synergistic mixture comprising an antibody, Anidulafungin (LY303366) and amphotericin B; for drug resistanct infections; induce immunology response; diagnosis of a patient with a Coccidioidomycosis infection |
| 07/31/2008 | US20080181882 treating a neuropsychiatric disorder with siRNA, polyamides, antisense RNA, synthetic peptide nucleic acids, antibody, Fab fragment; enhancing tyrosine phosphorylation; long lasting treatment, inhibit side effects; biodrugs; gene therapy; drug screening |
| 07/31/2008 | US20080181881 drug screening a polypeptide antagonist or antibody that binds to the acid-sensing ion channel 3; antisense nucleic acid that inhibit or decreases the expression level of the acid-sensing ion channel 3; treating glucose intolerance of metabolic disorders |
| 07/31/2008 | US20080181880 Inducing rapid bone formation; contains bone anabolic agent and a mechanical alteration device for altering contents of a bone marrow cavity, increase in osteoblast activity; antiresorptive agent for prevent resorption; drug targeting of specific bones |
| 07/31/2008 | US20080181877 bioassay of forskolin or phorbol 12-myristate 13-acetate; increase sensitivity of the protein kinase A signalling pathway, increase insulin sensitivity, thermogenesis; obesity, type 2 diabetes, insulin resistance, hypertriglyceridemia, cancer, increase plasma levels of free fatty acids |
| 07/31/2008 | US20080181873 produce more stem cells in vivo or in vitro by culture, for transplantation into patient; increase neurogenesis or new olfactory neuron numbers; stroke, neurodegenerative disease of Alzheimer's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis, and Parkinson's disease |
| 07/31/2008 | US20080181871 Focal calcium channel modulation |
| 07/31/2008 | US20080181868 Macrocylic oximyl hepatitis c protease inhibitors |
| 07/31/2008 | US20080181867 preparing a pre-concentrate by emulsifying an oil phase castor oil with water and a water soluble pharmaceutically active substance cyclosporine A, then dilute to desired concentration; eye drops for eye disorders; less time and low energy consuming, no negative impact on the chemical stability |
| 07/31/2008 | US20080181866 treating hepatitis C virus infections; 2-[4-(4-Cyclopropylcarbamoyl-phenyl)-thiazol-2-ylcarbamoyl]-indole-1-carboxylic acid benzyl ester; inhibiting viral and host cell targets in the replication cycle |
| 07/31/2008 | US20080181864 Reducing mitochondrial membrane potential in mammalian cell by administering an major histocompatibility complex (MHC) class II HLA-DR (human leukocyte antigen) ligand; control disease by manipulating mitochondrial metabolism; drug screening antitumor drug; treating human breast cancer |
| 07/31/2008 | US20080181860 first component containing flavonoids from green tea and second component solvent system has water and surfactant are maintained separately and are mixed prior to use; stable and ability to penetrate the skin; topical dermatological skin inflammation, wound healing, antioxidant effect, skin disorders |
| 07/31/2008 | US20080181859 cosmetic and pharmaceutical compositions containing addition copolymer consisting of monomers of isobornyl (meth)acrylates, and (meth)acryloxypropyltrimethoxysilane, or a-c copolymer of a polysiloxane, or a polysilsesquioxane; film forming, compatible, homogeneity, comfortable, no tightness |
| 07/31/2008 | US20080181854 antiinflammatory ascomycin derivative pimecrolimus in the form of a foam; inflammatory and hyperproliferative skin diseases and of cutaneous manifestations of immunologically-mediated diseases |
| 07/31/2008 | US20080181852 water soluble polyglutamnylglutamine conjugated to drugs, polydentate ligands, targeting, optical imaging, magnetic resonance imaging or stabilizing agents, having improved bioavailability |
| 07/31/2008 | US20080181849 Methods, kits and compositions comprising crotamine |
| 07/31/2008 | US20080181826 uniform heating and cooling of the containers, preventing stress cracks; gentle; use of radiant heat-generating heating units that act on the container bottoms in concert with the hot air from the ventilating fan units |
| 07/31/2008 | US20080179246 Method of obtaining a natural hydroxytyrosol-rich concentrate from olive tree residues and subproducts using clean technologies |
| 07/31/2008 | DE202008007318U1 Langzeitstabile pharmazeutische Zubereitung mit dem Wirkstoff Glyceroltrinitrat Long-term stable pharmaceutical composition containing the active ingredient nitroglycerin |
| 07/31/2008 | DE202006020318U1 Therapeutische Zusammensetzungen und ihre Verwendung Therapeutic compositions and their use |
| 07/31/2008 | DE102007010815B3 New N-phenylsulfonyl-3-amidino-phenylalanine piperidide derivatives useful as antitumor agents |
| 07/31/2008 | DE102007005329A1 Use of adenosine for erythrocytes protection, and for prevention of sepsis, hemolytic uremic syndrome, microcirculation disturbances, diabetic vascular disease or anemia, has antibiotic or cytostatic drug |
| 07/31/2008 | DE102007003795A1 Verwendung von Folsäure, Vitamin B6 und Vitamin B12 Use of folic acid, vitamin B6 and vitamin B12 |
| 07/31/2008 | DE102007002260A1 Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms Use of substituted Pyranonsäurederivaten for the preparation of medicaments for the treatment of metabolic syndrome |
| 07/31/2008 | DE102004039196B4 Neue Formulierung für L-Tryptophan New formulation of L-tryptophan |
| 07/31/2008 | CA2713199A1 Topical formulation |
| 07/31/2008 | CA2676620A1 Methods for preventing and treating neurodegenerative disorders |
| 07/31/2008 | CA2676535A1 Organometallic compounds |
| 07/31/2008 | CA2676527A1 N-amino tetrahydrothiazine derivatives, method of manufacture and use |
| 07/31/2008 | CA2676512A1 Synthesis of 1.alpha.-fluoro-25-hydroxy-16-23e-diene-26,27-bishomo-20-epi-cholecalciferol |
| 07/31/2008 | CA2676485A1 Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia |
| 07/31/2008 | CA2676417A1 Tgr5 modulators and methods of use thereof |
| 07/31/2008 | CA2676387A1 Combination therapy |
| 07/31/2008 | CA2676357A1 Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
| 07/31/2008 | CA2676353A1 Production of rosmarinic acid from spearmint and uses thereof |
| 07/31/2008 | CA2676257A1 Anthranilamide inhibitors of aurora kinase |
| 07/31/2008 | CA2676252A1 Substituted arylcyclopentenes as therapeutic agents |
| 07/31/2008 | CA2676244A1 Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
| 07/31/2008 | CA2676239A1 Self-assembling amphiphilic polymers as antiviral agents |
| 07/31/2008 | CA2676222A1 Substituted aminopyrimidines as cholecystokinin-1 receptor modulators |
| 07/31/2008 | CA2676214A1 Novel heteroaryl substituted imidazo [1,2 -a] pyridine derivatives |
| 07/31/2008 | CA2676208A1 Compound, a1 adrenergic receptor antagonist agent, and composition |
| 07/31/2008 | CA2676199A1 Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 07/31/2008 | CA2676175A1 Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers |
| 07/31/2008 | CA2676172A1 Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenyl-piperidin-3s-yl-) |
| 07/31/2008 | CA2676105A1 The tetracyclic anthraquinones possessing anti-cancer effect |
| 07/31/2008 | CA2676066A1 Nuclear receptor binding agents |
| 07/31/2008 | CA2676061A1 Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
| 07/31/2008 | CA2676051A1 Insulin sensitisers and methods of treatment |
| 07/31/2008 | CA2676020A1 Heterocyclidene-n-(aryl) acetamide derivative |
| 07/31/2008 | CA2675981A1 Thiophene derivatives useful as ocular hypotensive agents |
| 07/31/2008 | CA2675934A1 Antiviral compounds |